Urology Times

Sunday Spotlight ?? : In this video,?Mark Tyson, M.D., M.P.H, and Jacob A. Moyer, BS,?highlight the background and key findings from the study, “Real-world outcomes of nadofaragene firadenovec in BCG-unresponsive non-muscle invasive bladder cancer,” which were presented by Moyer at the?2025 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium?in San Francisco, California. Tyson is a urologic oncologist at the Mayo Clinic in Arizona, and Moyer is a research intern at Mayo Clinic Scottsdale in Arizona. For more ?? : https://lnkd.in/gNGnZafc

We are proud to work alongside Amy M. Pearlman, MD, whose expertise in urology has made a lasting impact. This International Women’s Day, we celebrate her dedication, leadership, and contributions to Urology Times. Check out her latest work here: https://bit.ly/43gwg9p #InternationalWomensDay #WomenInMedicine

The future of #telehealth coverage under Medicare remains in limbo as Congress weighs the decision to extend many of the flexibilities implemented during the pandemic. In 2 recent studies, investigators have shown that widespread adoption of telehealth did not increase Medicare visits and may actually reduce overall Medicare spending, countering key concerns about its continued coverage. According to Chad Ellimoottil, MD, MS, of Michigan Medicine, these findings can inform policymakers as they consider the future for continued coverage. Read more on the findings: https://lnkd.in/eVDvJDBy

Join us for an exclusive roundtable on Advancements in Non-Muscle Invasive Bladder Cancer (NMIBC), moderated by Raj Satkunasivam. This small-group session will cover challenges in NMIBC management, evolving treatments, and collaboration between local urologists. ?? Date & Time: Thursday, March 20, 2025 | 7:00 - 9:00 PM CT ?? Venue: Potente, 1515 Texas Ave, Houston, TX ?? Limited Seats (12 spots)! ?? Register Now: bit.ly/4kvAhwQ #Urology #BladderCancer #NMIBC #UrologyTimes

Article of the Week ?? : The Neuspera Medical Inc. percutaneous sacral neuromodulation device demonstrated promising efficacy in the management of urge urinary incontinence (#UUI), according to 6-month results from the pivotal phase 2 SANS UUI trial, presented at #SUFU25. ?? : https://lnkd.in/g3gmbeAw

Ashish Kamat, MD, MBBS provides expert insights into the recent shifts and evolution in the bladder cancer treatment landscape and the critical role of shared decision-making and personalized care, in this sponsored article. Read more: bit.ly/4hopKRQ #Sponsored by Johnson & Johnson

Amy Krambeck, MD, of Northwestern University - The Feinberg School of Medicine, recently shared her perspective on the role of preoperative imaging when performing HoLEP for benign prostatic hyperplasia (#BPH). Specifically, she stressed the importance of knowing the size of the prostate prior to surgery. Listen to her thoughts here: https://lnkd.in/eNyXaX4s

In an interview at #GU25, David Braun, MD, PhD, of Yale School of Medicine Department of Urology shared findings on the biological mechanisms of chromophobe renal cell carcinoma, highlighting unique differences compared with other #RCC histologies. The hope, he explains, is that these data can be used to guide therapeutic development for this disease, which currently faces a lack of effective options. Read more from Dr. Braun here: https://lnkd.in/e6etPAfx #KCSM #ChRCC

In a recent interview, Jason Hafron, MD, of Michigan Institute Of Urology shared his predictions for coming advancements in prostate cancer care and research in 2025. These trends included breakthroughs in diagnostic tests, improvements in PSMA-PET imaging, and treatment advances in high-risk and very high-risk?disease, among others. Learn more from Dr. Hafron here ?? : https://lnkd.in/eCtrTtxp #PCSM

Welcome back to?Urology Times’ monthly #FDA update! Last month’s key developments in urology included: ? Orphan drug and rare pediatric disease designations for ABO-101 for PH1 ? FDA clearance for Ibex Prostate Detect ? FDA fast track designation for 67Cu-SAR-bisPSMA?for mCRPC ? Priority review for?89Zr-DFO-girentuximab?for PET imaging of ccRCC Stay informed—read the full FDA recap and subscribe to our newsletters for more updates! https://lnkd.in/e3M-VsWr #PCSM #KCSM